TransCode Therapeutics Acquires Polynoma
TransCode Therapeutics, Inc. announced on October 8 that it entered into an agreement to acquire Polynoma LLC. Polynoma is a privately held biotechnology immuno-oncology company. Polynoma is developing a late-stage candidate, seviprotimut-L, a novel polyvalent shed antigen vaccine for the adjuvant treatment of stage IIB and IIC melanoma. TransCode is a clinical-stage oncology company focused on treating metastatic disease. The company is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which... Read More »
Pfizer Buys Metsera and its Next-Generation Obesity Portfolio
Pfizer Inc. and Metsera, Inc. jointly today announced on September 22 that the companies have entered into a definitive agreement under which Pfizer will acquire Metsera. Under the terms of the agreement, Pfizer will acquire all outstanding shares of Metsera common stock for $47.50 per share in cash at closing, for an initial enterprise value of $4.9 billion with a contingent value right of up to $22.50 per share in additional payments. The Boards of Directors of both Metsera and Pfizer have unanimously approved the transaction, which is expected to close in the fourth quarter of 2025. Metsera is a clinical-stage biopharmaceutical company accelerating the next generation of medicines for... Read More »
Kite Acquires Interius BioTherapeutics to Advance In Vivo Platform
Kite Pharma, a wholly owned subsidiary of Gilead Sciences, announced that it has entered into a definitive agreement to acquire Interius BioTherapeutics for a total of $350 million in cash consideration. Interius BioTherapeutics is a clinical-stage biotechnology company engineering targeted, programmable vectors for the precision delivery of genetic medicines to treat an array of challenging diseases in oncology, autoimmunity and beyond. Leveraging a proprietary platform, Interius has created a differentiated off-the-shelf therapeutic modality designed for broad patient access. The company’s lead programs aim to overcome the current limitations of ex vivo chimeric antigen receptor (CAR)... Read More »
Concentra Biosciences Acquires iTeos Therapeutics for $434 Million
Concentra Biosciences, LLC announced that it entered into an agreement to acquire iTeos Therapeutics for more than $434.4 million. iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of tumor immunology and immunosuppressive pathways to design novel product candidates with the potential to restore the immune response against cancer. According to iTeos Therapeutics’ financial reports, the company reported $35 million in revenue for the full year 2024. Concentra Biosciences is owned by Tang Capital... Read More »
Supernus Pharmaceuticals to Acquire Sage Therapeutics for $561 Million
Supernus Pharmaceuticals announced on June 16 that it has entered into an agreement to acquire Sage Therapeutics, based in Cambridge, Massachusetts. Supernus to acquire Sage through a tender offer for $8.50 per share in cash (or an aggregate of approximately $561 million), plus one non-tradable contingent value right (CRV) collectively worth up to $3.50 per share in cash (or an aggregate of approximately $234 million). The total consideration is $12.00 per share in cash (or an aggregate of up to approximately $795 million). The CVR is payable upon achieving certain net sales and commercial milestones. Sage Therapeutics is a biopharmaceutical company committed to developing... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
